Time to gain some momentum!, page-342

novice & cityhunter

After investing in other legal opiate related stocks, it is my opinion they will not release full details of exactly how much they sell raw product for, or what price they bought at, and will cite 'commercial in confidence' as the reason. They believe that disclosing such information may lead to a competitor gaining an advantage ie Big Pharma like GSK.

It was always my understanding that MXC would be geared toward R & D and not directly growing, producing or manufacturing anything but research into the potential benefits of MC.

Mr Lambert laid a fair amount of coin on this, so I am backing his judgement. Otherwise I would not be here.

Schweik